This recommended biotech stock (Alkermes) has delivered the goods with outstanding positive top line data in a treatment for depressions, explains leading biotech analyst John McCamant, editor of The Medical technology Stock Letter.
Category: Publicity
Pacira: Safer than Opioids? (05-19-2016)
The move away from opiods is gaining momentum, explains biotech sector John McCamant, editor The Medical Technology Stock Letter.
Top Picks 2016: Anthera (1-15-2016)
Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-Anthera Pharmaceuticals. #ANTH
Biotech Bets: A Mispriced Trio (11-9-2015)
Recent volatility has created an environment for biotech stocks in which company fundamentals are mispriced relative to their stock prices, according to John McCamant. Here, the editor of The Medical Technology Stock Letter discusses the current state of the biotech market and highlights a trio of well-positioned stocks currently being undervalued by the market.
Catalysts in Biotech (8-19-2016)
John McCamant of BioInvest’s Medical Technology Stock Letter, updates us on the state of the sector, the primary catalysts he sees over the rest of the year, and a trio of favorite stocks poised for potentially exciting results.
Opinion: Dozens of biotech companies are ‘free’ for investors’ taking (2-16-2016)
Dozens of biotech companies are ‘free’ for investors’ taking
2015’s Top Performers (1-12-2016)
John McCamant, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his biotech stock picks for 2015, one of which (FPRX) that has risen 50%. #FPRX #PCYC
Life Sciences Report (9-16-15)
An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.
Opinion: Four reasons for investors to buy biotechnology stocks now (05-20-2016)
Four reasons for investors to buy biotechnology stocks now: Beaten-down biotechnology stocks have been so cheap for so long, rattled investors pray every day that a big drug company with firepower will swoop in and buy one to spark interest in the industry.
Top Picks 2016: Pharmaceuticals (1-28-2016)
Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-The Medicines Company. #MDCO
2015’s Top Performers (12-30-2015)
Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his two biotech stock picks for 2015 that have risen 33% and 41%. #NVAX #MDCO
MoneyShow – Top Picks Mid-Year Winners: Jay Silverman (7-6-15)
In January, MoneyShow asked all of the nation’s leading advisors to select a favorite stock for 2015. In this special series of interviews we are talking with the five advisors who had the top performing stock picks as of mid-year. Here, we talk with Jay Silverman, editor of The Medical Technology Stock Letter, to discuss a top performing biotechnology company.